Css LLC Atea Pharmaceuticals, Inc. Call Options Transaction History

Css LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.35 $7,000 - $8,375	-2,500 Reduced 5.07%	46,800 $142,000
Q3 2023 Nov 14, 2023	BUY	$3.0 - $3.79 $4,500 - $5,685	1,500 Added 3.14%	49,300 $147,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $153,438 - $241,867	47,800 New	47,800 $178,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $174,350 - $291,323	-31,700 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $206,323 - $1.2 Million	26,900 Added 560.42%	31,700 $283,000
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $249,560 - $410,202	-11,700 Reduced 70.91%	4,800 $169,000
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $317,130 - $974,820	16,500 New	16,500 $354,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $283M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.